Palantir's NHS Federated Data Platform (FDP) has incorporated patient records from UK general practices without significant public awareness. The £330 million initiative, awarded to a Palantir-led consortium in December 2023, aims to centralize NHS data for better planning, but its implementation has sparked debate over transparency and data privacy.
The integration of sensitive patient data into a platform managed by a private company, particularly one with a history of government contracts, raises significant concerns about data privacy, security, and the potential for misuse, impacting public trust in the NHS and its handling of personal health information.
Patient records from UK general practices have been integrated into Palantir’s NHS Federated Data Platform (FDP) without significant public awareness. The FDP, a £330 million initiative awarded to a Palantir-led consortium in December 2023, aims to consolidate and streamline NHS data for improved planning and decision-making.
According to NHS documentation, some data within the FDP may originate from GP records, and GP data lawfully shared with NHS trusts could also be included. This has raised questions about the adequacy of communication regarding the integration of GP data to the public and healthcare professionals.
Under the contract, Palantir functions as a data processor, meaning it is restricted from using the data for its own commercial purposes. However, concerns persist regarding the transparency of the contract, particularly its redacted data protection clauses, which critics argue obscure Palantir’s access and usage rights.
The integration of GP data into the FDP has amplified worries about potential misuse, partly due to Palantir's past work with US government agencies. Palantir UK’s executive vice-chair, Louis Mosley, has asserted that the company has no interest in patient data and likens its role to using standard NHS software. Nevertheless, skepticism remains.
In response to the controversy, a cross-party parliamentary committee has urged the UK government to disclose Palantir’s access to patient data and the legal basis for its utilization. As the FDP's expansion continues, the debate surrounding data governance, privacy, and accountability within the NHS is expected to intensify.